The MarketReader Minute
💊 Syndax Plunges on FDA Delay, Anavex Soars on Positive Alzheimer's Trial, Exact Sciences Falls | Biotech Sector Insights
Gilead Sciences is making a $30 million milestone payment to Compugen, following FDA clearance for an investigational new drug application for COM503. This development enhances Gilead's oncology portfolio with a potential first-in-class anti-IL-18 binding protein antibody.